CTRI/2023/11/059857已完成4 期
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of GUT RESET Capsules in Alleviating the Gastro-Esophageal Reflux (GER)-Related Symptoms. ? - NI
Herbal Creations (A Unit of Kumaon Exports Pvt. Ltd.)0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Apparently healthy adults of any gender 18 - 60 years of age, willing to provide consent affected by symptoms of GER.
- •2. History of GER-related symptoms for at least 1 month prior to study inclusion and otherwise healthy
- •3. Not participated in any other interventional trials in the last 1 month before trial recruitment
- •4. Willing to discontinue medications like H2 Receptor antagonists, Antacids, Pro-kinetics, and supplements that have been prescribed for the GER related symptoms and not on any of these agents in the last 10 days before randomization.
- •5. Presence of symptoms of at least 2 days in the week preceding randomization
排除标准
- •1. Presence of any of the following red flag symptoms such as Iron deficiency anemia, weight loss, persistent vomiting, GI bleed, epigastric mass
- •2. Women of reproductive age who are pregnant / lactating / not willing for adequate contraception.
- •3. History of allergy to any medications including alternate system of medications
- •4. History of uncontrolled diabetes (Random Blood Sugar > 200mg%)
- •5. Inability to follow the protocol or expressed inability to complete all follow-ups.
- •6. Abnormalities in the liver function tests (defined as total bilirubin >1mg% or SGOT / SGPT > 3 times the upper limit of normal)
- •7. Abnormal renal function test (Creatinine > 1.4mg%)
- •8. Congestive cardiac failure and other medical conditions which the investigator feels will affect the pharmacokinetic parameters of the study drug.
- •9. History of erosive esophagitis, Barrett’s esophagus, tumoral pathologies, atypical pathology without heartburn and ulcer
- •10. Presence of HIV, HbsAG or HCV positive and any other medical/ surgical condition the investigator feels may cause harm to the participant.
研究者
相似试验
已完成
3 期
A research study investigating troriluzole as a possible treatment for Obsessive Compulsive Disorder2024-514585-39-00Biohaven Pharmaceuticals Inc.100
进行中(未招募)
3 期
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)Atopic DermatitisJPRN-jRCT2031200389Masaki Takeshi280
已完成
不适用
A clinical study to evaluate the efficacy and safety of Turmeric Capsules (TurmXtra 60 N) Delayed onset muscle soreness in healthy recreationally active subjectsCTRI/2021/12/038892Inventia Healthcare Ltd30
招募中
1 期
A research study investigating troriluzole as a possible treatment for Obsessive Compulsive DisorderCTIS2024-514585-39-00Biohaven Pharmaceuticals Inc.700
进行中(未招募)
不适用
A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFRCentral neuropathic pain due to Multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2008-002560-34-BEEli Lilly and Company238
